As demand for weight loss and diabetes drugs surges, Eli Lilly and Novo Nordisk dominate the market. Discover the challenges, competition, and future of this booming industry.
Eli Lilly's stock surged 3.9% after an outstanding Q3 earnings report, surpassing analysts' expectations with $7.02 per share and $17.6 billion in sales. The company raised its yearly guidance, signaling strong growth potential.
Eli Lilly's third-quarter results exceeded estimates, driven by strong demand for Zepbound and Mounjaro. The company raised its revenue forecast, fueling a 5% rise in shares. Discover how Eli Lilly is maintaining its lead in the competitive obesity drug market.
Pfizer's unexpected deal with the Trump administration on drug pricing sends shockwaves through the pharmaceutical industry, pressuring competitors to follow suit amidst potential regulatory threats. What’s next for drug prices?
Eli Lilly announces a groundbreaking $5 billion investment in a new manufacturing plant near Richmond, aimed at boosting U.S. production of essential pharmaceutical ingredients.
In a day marked by significant market movements, EchoStar's stock skyrocketed following AT&T's $23 billion purchase of wireless licenses. Eli Lilly also saw gains with promising diabetes drug results, while Nvidia's upcoming report looms large.
Eli Lilly's new obesity pill, orforglipron, faces tough competition but could disrupt the weight loss market. Despite underwhelming trial results, analysts see potential for success due to manufacturing advantages and pricing strategies.
Eli Lilly announces a dramatic price increase for its diabetes medication Mounjaro in the UK, raising the monthly cost from £122 to £330. This change affects private buyers but not NHS prescriptions. Learn more about the implications!
In a surprising move, Novo Nordisk CEO Lars Fruergaard Jorgensen steps down as the company faces significant market challenges and competition from Eli Lilly's Zepbound. With share prices plummeting, the board seeks new leadership to navigate the turbulent landscape.
Pfizer Inc. has decided to stop the development of its obesity pill, danuglipron, after safety concerns emerged from a clinical trial. This move comes as competition heats up with Novo Nordisk and Eli Lilly's successful weight-loss treatments.
